G. Martiny-Baron

发表

The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis

G. Martiny-Baron, Philipp Holzer, E. Billy, 2010, Angiogenesis.

PTK 787 / ZK 222584 , a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration

Martin R. Schneider, J. Mestan, F. Totzke, 2000 .

Biochemical characterization and purification of the neuronal sodium-dependent noradrenaline transporter.

G. Martiny-Baron, H. Bönisch, B. Blum, 1990, Journal of neural transmission. Supplementum.

Molecular aspects of the neuronal noradrenaline transporter.

G. Martiny-Baron, H. Bönisch, G. Paulus, 1991, Journal of neural transmission. Supplementum.

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

W. Sellers, D. Fabbro, Christopher J. Wilson, 2011, Molecular Cancer Therapeutics.

Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976.

G. Martiny-Baron, G. Kochs, H. Mischak, 1993, The Journal of biological chemistry.

Cell-Demanded Liberation of VEGF121 From Fibrin Implants Induces Local and Controlled Blood Vessel Growth

Jeffrey A. Hubbell, Martin Ehrbar, J. Hubbell, 2004, Circulation research.

Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli.

G. Martiny-Baron, G. Siemeister, D. Marmé, 1996, Biochemical and biophysical research communications.

VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane.

G. Martiny-Baron, D. Marmé, A. Eichmann, 1996, Developmental biology.

Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity.

W. Kolch, G. Martiny-Baron, H. Mischak, 1993, The Journal of biological chemistry.

A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.

J. Mestan, G. Martiny-Baron, C. Schnell, 2016, Journal of medicinal chemistry.

Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.

G. Martiny-Baron, G. Siemeister, D. Marmé, 1997, Cancer research.

Vascular Endothelial Growth Factor UpRegulates Its Receptorfms .-like Tyrosine Kinase 1 ( FLT-1 ) and a Soluble Variant of FLT-1 in Human Vascular Endothelial Cells 1

Gerhard, G. Martiny-Baron, K. Weindel, 2006 .

Monoclonal antibody TOP 71 recognizes a tonoplast protein of wide distribution in the plant kingdom

G. Martiny-Baron, D. Volkmann, G. Scherer, 1993, Planta.

A new set of regulatory molecules in plants: A plant phospholipid similar to platelet-activating factor stimulates protein kinase and proton-translocating ATPase in membrane vesicles

G. Martiny-Baron, G. Scherer, B. Stoffel, 1988, Planta.

Donor stromal cells from human blood engraft in NOD/SCID mice.

G. Martiny-Baron, I. Fichtner, R. Henschler, 2000, Blood.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

G. Martiny-Baron, K. Altmann, R. Cozens, 2000, Journal of medicinal chemistry.

Inhibition of angiogenesis in lipodermatosclerosis: implication for venous ulcer formation.

M. Idzko, G. Martiny-Baron, F. May, 2009, International journal of molecular medicine.

A plant protein kinase and plant microsomal H+ transport are stimulated by the ether phospholipid platelet-activating factor

G. Martiny-Baron, G. Scherer, 1988, Plant Cell Reports.

The Molecular Size of the Neuronal Noradrenaline Carrier

G. Martiny-Baron, H. Bönisch, B. Blum, 1991 .

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

D. Fabbro, G. Martiny-Baron, J. Brueggen, 2004, Cancer cell.

Proton transport and phosphorylation of tonoplast polypeptides from zucchini are stimulated by the phospholipid platelet-activating factor.

G. Martiny-Baron, D. Hecker, M. Manolson, 1992, Plant physiology.

Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.

G. Martiny-Baron, G. Siemeister, D. Marmé, 1996, Cancer research.

Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

J. Mestan, D. Fabbro, G. Martiny-Baron, 2010, Biochimica et biophysica acta.

Targeting cancer with small-molecular-weight kinase inhibitors.

D. Fabbro, G. Martiny-Baron, S. Cowan-Jacob, 2012, Methods in molecular biology.

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J. Mestan, F. Totzke, G. Martiny-Baron, 2000, Cancer research.

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

Stephen J. Elledge, Mikhail Pachkov, Erik van Nimwegen, 2012, Nature Medicine.

The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities

G. Martiny-Baron, G. Siemeister, D. Marmé, 1998, Cancer and Metastasis Reviews.

Identification and characterization of NVP-BKM 120 , an orally available pan class I PI 3-Kinase inhibitor

W. Sellers, D. Fabbro, R. Schlegel, 2011 .

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

G. Martiny-Baron, J. Wood, J. Drevs, 2000, Cancer research.

Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.

G. Martiny-Baron, A. Menrad, G. Siemeister, 1999, Cancer research.

Therapies directed at vascular endothelial growth factor

G. Martiny-Baron, J. Wood, P. Manley, 2002, Expert opinion on investigational drugs.

Classical PKC isoforms in cancer.

D. Fabbro, G. Martiny-Baron, 2007, Pharmacological research.

Effects of PTK 787 / ZK 222584 , a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , on Primary Tumor , Metastasis , Vessel Density , and Blood Flow in a Murine Renal Cell Carcinoma Model 1

G. Martiny-Baron, J. Wood, J. Drevs, 2000 .

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis

W. Kolch, G. Martiny-Baron, D. Marmé, 2004, Breast Cancer Research and Treatment.

An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.

G. Martiny-Baron, G. Siemeister, M. Schirner, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Novel antibodies directed against the extracellular domain of the human VEGF-receptor type II.

G. Martiny-Baron, A. Menrad, G. Siemeister, 1997, Hybridoma.

VEGF-mediated tumour angiogenesis: a new target for cancer therapy.

G. Martiny-Baron, D. Marmé, Dieter Marmé, 1995, Current opinion in biotechnology.

Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates.

G. Martiny-Baron, U. Eppenberger, J. Schlaeppi, 1996, Clinical chemistry.

Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors

F. Totzke, G. Martiny-Baron, D. Marmé, 2004, Angiogenesis.

The α-Helical Domain Near the Amino Terminus Is Essential for Dimerization of Vascular Endothelial Growth Factor*

G. Martiny-Baron, G. Siemeister, D. Marmé, 1998, The Journal of Biological Chemistry.

Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1*

E. Kremmer, F. Totzke, G. Martiny-Baron, 1997, The Journal of Biological Chemistry.

Active interaction of human A375 melanoma cells with the lymphatics in vivo

G. Martiny-Baron, G. Siemeister, D. Marmé, 2000, Histochemistry and Cell Biology.

Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: A rational basis for combining RAD001 and PTK787/ZK222584

H. Lane, G. Martiny-Baron, C. Schnell, 2005 .

Advances in Brief Reversion of Deregulated Expression of Vascular Endothelial Growth Factor in Human Renal Carcinoma Cells by von Hippel-Lindau Tumor Suppressor Protein 1

G. Martiny-Baron, G. Siemeister, B. Barleon, 2006 .

Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity.

P. Kuhn, G. Martiny-Baron, J. Chrencik, 2006, Structure.

Podocyte EphB4 signaling helps recovery from glomerular injury.

G. Martiny-Baron, Philipp Holzer, U. Huynh-Do, 2012, Kidney international.

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

H. Lane, G. Martiny-Baron, C. Schnell, 2009, Clinical Cancer Research.

Blood vessel maturation in a 3‐dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness

H. Augustin, G. Martiny-Baron, S. Kimmina, 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Characterization of kinase inhibitors using reverse phase protein arrays.

D. Fabbro, G. Martiny-Baron, D. Haasen, 2011, Methods in molecular biology.

Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.

G. Martiny-Baron, G. Fendrich, T. Troxler, 2016, Journal of medicinal chemistry.

Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood

G. Martiny-Baron, G. Siemeister, D. Marmé, 2004, Angiogenesis.

Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro.

G. Martiny-Baron, G. Siemeister, D. Marmé, 2000, Biochimica et biophysica acta.

Overexpression of Protein Kinase CS and-6 in NIH 3 T 3 Cells Induces Opposite Effects on Growth , Morphology , Anchorage Dependence , and Tumorigenicity *

G. Martiny-Baron, J. Pierce, J. Mushinski, 2001 .

Angiopoietin-1 and Angiopoietin-2 Share the Same Binding Domains in the Tie-2 Receptor Involving the First Ig-like Loop and the Epidermal Growth Factor-like Repeats*

H. Augustin, G. Martiny-Baron, D. Marmé, 2003, The Journal of Biological Chemistry.

Extended kinase profiling of the Bcr-Abl inhibitor nilotinib

D. Fabbro, G. Martiny-Baron, T. Meyer, 2007 .

Inhibition of tumor growth and angiogenesis by soluble EphB4.

H. Augustin, G. Martiny-Baron, D. Marmé, 2004, Neoplasia.

Effects of Protein and Gene Transfer of the Angiopoietin-1 Fibrinogen-like Receptor-binding Domain on Endothelial and Vessel Organization*

M. Fussenegger, J. Hubbell, K. Frei, 2005, Journal of Biological Chemistry.

K+/H+ exchange transport in plant membrane vesicles is evidence for K+ transport

G. Martiny-Baron, G. Scherer, 1985 .

Inhibition of tumor growth and angiogenesis by soluble EphB4.

H. Augustin, G. Martiny-Baron, D. Marmé, 2004, Neoplasia.

Stimulation of In Vitro H+ Transport in Zucchini Microsomes by the Ether Lipid Platelet Activating Factor and a Soluble Protein

G. Martiny-Baron, G. Scherer, 1987 .

CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and BFGF-induced angiogenesis

J. Mestan, G. Martiny-Baron, J. Wood, 2002 .

Podocyte EphB4 signaling helps recovery from glomerular injury.

G. Martiny-Baron, Philipp Holzer, U. Huynh-Do, 2012, Kidney international.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis

Stover, Roth, J. Mestan, 2000, Journal of medicinal chemistry.